Future directions for unsealed source radionuclide therapy for bone metastases

European Journal of Nuclear Medicine

Volumn 29, Issue 10, 2002, Pages 1271-1275

  McCready, V R ^a   O'Sullivan, J M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; DOXORUBICIN; ESTRAMUSTINE; ETIDRONIC ACID RE 186; ETIDRONIC ACID RE 188; KETOCONAZOLE; LEXIDRONAM SAMARIUM SM 153; OPIATE; PHOSPHORUS 32; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RHENIUM 188; STEROID; STRONTIUM 89; STRONTIUM CHLORIDE; UNCLASSIFIED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT;

ANALGESIA; BEAM THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DOSIMETRY; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPARATHYROIDISM; INCIDENCE; KIDNEY FUNCTION; NEUROBLASTOMA; NUCLEAR MEDICINE; OSTEOBLAST; OSTEOSARCOMA; PAIN; PALLIATIVE THERAPY; POLYMERASE CHAIN REACTION; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; THROMBOCYTOPENIA; PAIN ASSESSMENT; ADJUVANT CHEMOTHERAPY; BONE TUMOR; CLASSIFICATION; FORECASTING; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; METHODOLOGY; QUALITY CONTROL; RADIATION RESPONSE; RADIOTHERAPY; RETREATMENT;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, RADIATION; FORECASTING; HUMANS; INJECTIONS, INTRAVENOUS; PAIN; QUALITY CONTROL; RADIOISOTOPES; RADIOTHERAPY; RETREATMENT;

EID: 0036384880     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0914-2     Document Type: Editorial

References (32)

1. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346:265-269.
2. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993; 20:66-74.
3. Bonica JJ. Importance of effective pain control. Acta Anaesthesiol Scand Suppl 1987; 85:1-16.
4. Turner JH, Claringbold PG. A phase II study study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphate. Eur J Cancer 1999; 27:1084-1086.
5. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357:336-341.
6. Burnet NG, Williams G, Howard N. Phosphorus-32 for intractable bony pain from carcinoma of the prostate. Clin Oncol (R Coll Radiol) 1990; 2:220-223.
7. Ben Josef E, Maughan RL, Vasan S, Porter AT. A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun 1995; 16:452-456.
8. Ben Josef E, Lucas DR, Vasan S, Porter AT. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation. Nucl Med Commun 1995; 16:457-463.
9. Mertens WC, Stitt L, Porter AT. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol 1993; 16:238-242.
10. McCready VR, Dearnaley D, Al Deen A, Treleaven J. Ablation of secondary bone cancer from carcinoma of the prostate using high activities of Re-186 HEDP and peripheral stem cell support. Nuklearmedizin 1999:A35.
11. de Klerk JMH, Zonnenberg AB, van het Schip AD, et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21:1114-1120.
12. O'Sullivan J, McCready VR, Flux GD, Norman AR, Buffa FM, Chittenden S. High activity rhenium-186 HEDP with autologous peripheral blood refractory prostate cancer metastatic to bone. Br J Cancer 2002; 86:1715-1720.
13. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20:189-196.
14. Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Jurgens H, Schober G. High-activity samarium-153 EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin 2001; 40:215-220.
15. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001; 42:1713-1721.
16. 89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma. Eur J Nucl Med 1989; 15:49-54.
17. McCready VR, O'Sullivan J, Dearnaley D, Treleaven J. Quantitative analysis of bone scans to determine if the dose to individual metastases from high activity Re 186 HEDP therapy depends upon the number of metastases. Radiology 2001; 221(P):344.
18. McCready VR, O'Sullivan J, Buffa F, et al. The relationship between skeletal metastatic load and therapeutic activity requirement in prostate cancer. Eur J Nucl Med 2001; 28:1054.
19. McCready VR, Dearnaley D, Treleaven J. Relationship between size and response of prostatic skeletal metastases treated with high activities of Re-186 with peripheral blood stem cell support. Eur J Nucl Med 2000; 27:965.
20. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol 1984; 142:773-776.
21. Berruti A, Cerutti S, Fasolis G, et al. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy. Gruppo Onco Urologico Piemontese (G.O.U.P). Anticancer Res 1997; 17:4697-4702.
22. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43:79-86.
23. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357:336-341.
24. Schellhammer PF. Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology 1988; 31:191-197.
25. Wood DP Jr, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994; 74:2533-2540.
26. Partin AW, Steinberg GD, Pitcock RV, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992; 70:161-168.
27. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337:295-300.
28. 89Sr) palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27:954-958.
29. Wheldon TE. Targeting radiation to tumours. Int J Radiat Biol 1994; 65:109-116.
30. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998; 25:1362-1367.
31. 188Re-HEDP in bone metastases. Eur J Nucl Med 2000; 27:266P.
32. Palmedo H, Guhlke S, Bender H, et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000; 27:123-130.